FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

vvasnington,	D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL									
OMB Number:	3235-0287								
Estimated average burden									
hours per response	. 0.5								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Ambrose Kristen						2. Issuer Name and Ticker or Trading Symbol VERTEX PHARMACEUTICALS INC / MA [VRTX]									all app Direc	licable)	ng Person(s) to I 10% C Other			
(Last)	(First) (Middle) VERTEX PHARMACEUTICALS						3. Date of Earliest Transaction (Month/Day/Year) 02/23/2024								X Officer (give title below) SVP & Chief Accounting Office					
INCORPORATED 50 NORTHERN AVENUE					4. If A	4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person						
(Street) BOSTO	(Street) BOSTON MA 02210				Rul	Rule 10b5-1(c) Transaction Indication									Form filed by More than One Reporting Person					
(City)																				
		Table	I - No	n-Deriva	tive S	Secui	rities	Acc	quired	, Dis	posed of	, or B	enefic	ially	Own	ed				
1. Title of Security (Instr. 3) 2. Transacti Date (Month/Day)						Execution Date			3. Transaction Code (Instr. 8)						5. Amount of Securities Beneficially Owned Following Reported		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)	
									Code	v	Amount	(A) or (D) Price			Transaction(s) (Instr. 3 and 4)				(111541. 4)	
Common Stock 02/23/20						024					828	D	\$43	1.79	8,848			D		
Common Stock 02/26/20					.024				S ⁽¹⁾		883 D		\$42	5.7	7,965		D			
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																				
1. Title of Derivative Security (Instr. 3)				4. Transaction Code (Instr. 8)		of Deriv Secu Acqu (A) of Dispo of (D) (Instr	of I		6. Date Exercisab Expiration Date (Month/Day/Year)		r) Amount Securitie Underlyi Derivativ Security 3 and 4)		Der Sec (Ins	Price of rivative curity str. 5)	9. Number derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	y	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)		
					Code	v	(A)	(D)	Date Expirat Exercisable Date		Expiration Date	Title	Amount or Number of Shares	1						

Explanation of Responses:

1. Transaction made pursuant to Ms. Ambrose's company approved trading plan under Rule 10b5-1, which was entered into on 02/28/2023.

Remarks:

/s/ Christiana Stevenson, Attorney-in-Fact

02/27/2024

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.